![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used for the development of APVO436, a recombinant T cell-engaging humanized bispecific antibody, for relapsed or refractory AML.
Lead Product(s): APVO436
Therapeutic Area: Oncology Product Name: APVO436
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $2.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 28, 2024
Details:
The company intends to use the net proceeds from the offering to advance the clinical development of its product candidate APVO436 for treating acute myeloid leukemia.
Lead Product(s): APVO436
Therapeutic Area: Oncology Product Name: APVO436
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $4.6 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 15, 2024
Details:
The company intends to use the net proceeds from the offering for the continued clinical development of its product candidate APVO436 for the treatment of acute myeloid leukemia.
Lead Product(s): APVO436
Therapeutic Area: Oncology Product Name: APVO436
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $4.6 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 11, 2024
Details:
ALG.APV-527 is a human bispecific antibody in the ADAPTIR™ format with a silenced immunoglobulin 1 (IgG1) Fc domain targeting the co-stimulatory receptor 4-1BB, expressed on immune cells. It is being evaluated for the treatment of solid tumors.
Lead Product(s): ALG.APV-527
Therapeutic Area: Oncology Product Name: ALG.APV-527
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alligator Bioscience
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2024
Details:
The Company intends to use the net proceeds for the continued clinical development of its product candidates including
Lead Product(s): APVO436
Therapeutic Area: Oncology Product Name: APVO436
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alliance Global Partners
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 04, 2023
Details:
APVO436 is a bispecific CD3xCD123 ADAPTIR drug candidate. The Company previously reported positive Phase 1b expansion trial results in AML and is planning to initiate Phase 2 trials in relapsed/refractory and frontline patients in 2H23 and 1H24 respectively.
Lead Product(s): APVO436
Therapeutic Area: Oncology Product Name: APVO436
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2023
Details:
Through the aquisition, XOMA gains the milestone rights to IXINITY® [coagulation factor IX (recombinant)], which is marketed by Medexus for the control and prevention of bleeding episodes and postoperative management in people with Hemophilia B, from Aptevo Therapeutics.
Lead Product(s): Coagulation Factor IX (recombinant)
Therapeutic Area: Genetic Disease Product Name: Ixinity
Highest Development Status: Phase IVProduct Type: Large molecule
Partner/Sponsor/Collaborator: XOMA
Deal Size: $9.6 million Upfront Cash: Undisclosed
Deal Type: Agreement March 30, 2023
Details:
ALG.APV-527 is a bispecific conditional 4-1BB agonist, actuvates upon simultaneous binding to 4-1BB and 5T4. 4-1BB has the ability to stimulate the antitumor-specific T cells and NK cells and 5T4 is an oncofetal tumor associated antigen overexpressed on numerous solid tumors.
Lead Product(s): ALG.APV-527
Therapeutic Area: Oncology Product Name: ALG.APV-527
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: Alligator Bioscience
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
APVO436 is a bispecific CD3xCD123 ADAPTIR currently in Phase 1b development in a multi-center, multi-cohort trial designed to evaluate safety, tolerability and efficacy in combination therapy and monotherapy for patients with AML.
Lead Product(s): APVO436,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: APVO436
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
Details:
APVO436 is an optimized ADAPTIR bispecific antibody candidate designed to redirect T-cell cytotoxicity through the dual targeting of CD3, a T-cell co-receptor that promotes cytotoxicity.
Lead Product(s): APVO436
Therapeutic Area: Oncology Product Name: APVO436
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022